Thermo Fisher Scientific Extends Reach in Pharma, Biotech with PPD Acquisition
Thermo Fisher Scientific is acquiring PPD Inc., a provider of clinical research services to the pharma and biotech industry. The companies’ boards of directors approved an acquisition agreement worth $17.4 billion and $47.50 per share, as well as Thermo Fisher’s assumption of approximately $3.5 billion of net debt. PPD will become part of Thermo Fisher’s laboratory products and services segment.
In a press release, Thermo Fisher said the acquisition provides it with a drug development platform, patient recruitment capabilities, and laboratory services, supporting its capabilities in pharma and biotech.
The transaction is expected to close by the end of 2021.
LATEST NEWS
- CLEO Heads to the East Coast
Apr 29, 2024
- Laser-Based Gas Analyzer Developed to Detect Air Pollution
Apr 29, 2024
- Qubits Could be Stored in Flash-Like Memory
Apr 29, 2024
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024